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Background: Bone marrow (BM) stem cells have been reported to contribute to tissue repair after kidney injury
model. However, there is no direct evidence so far that BM cells can trans-differentiate into renal stem cells.
Methods: To investigate whether BM stem cells contribute to repopulate the renal stem cell pool, we transplanted
BM cells from transgenic mice, expressing enhanced green fluorescent protein (EGFP) into wild-type irradiated
recipients. Following hematological reconstitution and ischemia-reperfusion (I/R), Sca-1 and c-Kit positive renal stem
cells in kidney were evaluated by immunostaining and flow cytometry analysis. Moreover, granulocyte colony
stimulating factor (G-CSF) was administrated to further explore if G-CSF can mobilize BM cells and enhance trans-
differentiation efficiency of BM cells into renal stem cells.
Results: BM-derived cells can contribute to the Sca-1+ or c-Kit+ renal progenitor cells population, although most
renal stem cells came from indigenous cells. Furthermore, G-CSF administration nearly doubled the frequency of
Sca-1+ BM-derived renal stem cells and increased capillary density of I/R injured kidneys.
Conclusions: These findings indicate that BM derived stem cells can give rise to cells that share properties of renal
resident stem cell. Moreover, G-CSF mobilization can enhance this effect.
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MobilizationBackground
Chronic kidney disease (CKD) and end-stage renal disease
(ESRD) are associated with considerable morbidity and
mortality. Current treatments fail to cure CKD and can’t
halt progression of CKD to ESRD [1]. Despite advances in
the understanding of glomerular and tubular injury and
regeneration, therapeutic advances have been limited be-
cause of the organ shortage for renal transplantation and
the complexity of kidney. Stem cell-based therapy is a new
strategy in the treatment of acute kidney injury and has* Correspondence: xuyong8816@sina.com; zongjinli@nankai.edu.cn
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reproduction in any medium, provided the orpotentially more value than single-agent drug therapy due
to the highly versatile response of cells to their environ-
ment [2]. The potential cellular sources for kidney regen-
eration include renal resident stem cells and extra-renal
stem cells. A number of recent studies have confirmed the
presence of cells bearing stem cell markers such as Sca-1,
c-Kit, and CD133 in the kidney [3-10]. These cells can dif-
ferentiate, proliferate, and eventually reline denuded
tubules, restoring the structural and functional integrity of
the kidney. However, the homeostasis of renal stem cells
in kidney is still under investigation.
Differentiation of bone marrow (BM) derived-cells into
cells of non-haematopoietic origin has been described in
several in vivo studies and gave rise to the thought that
the BM-derived cells population could be involved in tis-
sue turnover and regeneration, including kidney [2,11-13].
It has been hypothesized that the stem cell repertoire ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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replenishing cells that differentiate from primate bone
marrow cells [14]. The movement of stem cells is critical
for homeostasis and repair in adulthood.
Identification of stem cells in kidney tissues is import-
ant for therapeutic applications and for understanding
developmental processes and tissue homeostasis. Previ-
ous research revealed that the BM-derived hematopoietic
stem cells (HSCs) can reside in kidney and differentiate
into mature cells [15]. Furthermore, the turning over of
BM derived stem cells into renal stem cells has not been
investigated so far. In this study, we sought to address
the plasticity of BM stem cells in trans-differentiating
into renal stem cells and BM derived stem cells in kidney
regeneration after acute kidney injury (AKI), as well as
the fortified effects of granulocyte colony-stimulating
factor (G-CSF) in mobilizing bone marrow stem cells
trans-differentiate into renal stem cells.
Methods
Isolation and transplantation of bone marrow cells
Animal protocols were approved by the Nankai Univer-
sity Animal Care and Use Committee. Mice were
anesthetized with inhaled isoflurane (2% to 3%). 8 to 10-
week-old female C57BL/6 J mice (The Laboratory Animal
Center of The Academy of Military Medical Sciences,
Beijing, China) (n = 30 per group) were irradiated with
9.5 Gy of γ-irradiation in 2 divided doses, 2 hours apart,
on the day of surgery. Bone marrow cells were isolated
from the femur and tibia of 8 to 10-week-old female
C57BL/6 J-TgN mice (The Laboratory Animal Center of
The Academy of Military Medical Sciences, Beijing,
China), transgenically expressing the chicken β-actin-
EGFP gene, by flushing with Iscove’s minimal essential
medium (IMEM). For bone marrow transplantation
(BMT), wild-type irradiated mice were injected with
0.2 ml PBS with or without 2.0 × 105 BM mononuclear
cells via tail veins at 2 hours after irradiation. Mice were
kept in a specific pathogen free facility and drinking water
containing enrofloxacin (0.15 mg/ml) and amoxicillin
(1 mg/ml) were given for 4 weeks to prevent infection.
Acute kidney ischemia/reperfusion experiments
Acute left kidney ischemia/reperfusion was carried out at
5-week after BMT. Mice were anesthetized by intraperi-
toneal injection with 300 mg/kg chloraldurat. Animals
were placed on a heating pad to maintain a constant
temperature and monitored with a rectal thermometer.
A midline abdominal incision was made, and left kidneys
were exposed. The left renal artery was separated from
the vein and clamped for 30 min followed by clamp re-
lease to allow reperfusion. Throughout ischemic period,
evidence of clamping was confirmed by visualizing dark
color of ischemic kidneys. After clamp removal, adequaterestoration of blood flow was checked before abdominal
closure. Sham-operated animals underwent anesthesia,
laparotomy, and renal pedicle dissection only.
Mobilization of bone marrow stem cells following
ischemic injury
For HSCs mobilization, mice received a subcutaneous
injection of 200 μg/kg recombinant G-CSF daily for
8 days from 5 before induction of ischemia. Control
mice received an injection of saline (n = 15 per group).
Flow cytometry analysis
To measure stem cells mobilization, flow cytometry ana-
lyses (FACScan flow cytometer, Becton Dickinson) were
performed on day 9 and 33 after administration of G-CSF.
The peripheral blood was stained with Alexa FluorW 647-
conjugated rat anti-mouse CD34, APC-labeled anti-mouse
c-Kit and CD45, and PE-labeled rat anti-mouse Sca-1, Flk-
1 and rat anti-mouse CD29, (all from BD Pharmingen).
5 weeks after BMT, bone marrow engraftment efficiency
in recipients was determined by analyzing GFP expression
of peripheral blood.
Isolation and characterization of renal progenitor cells
after BMT
Nine weeks after BMT, the intact kidney tissue was
minced and added to 10 ml of a 4 mg/ml solution of dis-
pase (sigma-Aldrich) in DMEM (Invitrogen). The minced
tissue and media were transferred to a 50-ml Erlenmeyer
flask and incubated for 1 h at 37°C. Following the incuba-
tion, the tissue was filtered through 40 μm nylon cell
strainer (BD Pharmingen) to remove cell segments [7].
Kidney cell suspensions were washed twice in DMEM
and stained with Sca-1, c-Kit, Flk-1, CD29, CD34 and
CD45 for FACS analysis.
Histology and immunohistochemistry
Four, 8 and 48 weeks after I/R, mice were euthanized
and the kidneys were thoroughly perfused with saline
to remove blood from the vascular beds. The specimens
of kidney were embedded into paraffin or OCT com-
pound (Miles Scientific), then sectioned to 5 μm slides
and processed for hematoxylin-eosin, Masson staining
and immunostaining. To track BM-derived cells in kid-
neys, rabbit anti-c-Kit antibody (Santa Cruz), mouse
monoclonal smooth muscle actin (α-SMA, Boster Co.,
China), monoclonal anti-mouse Sca-1 (Cedarlane), and
rat anti-mouse CD45, CD29, CD105 (all from BD Phar-
mingen) were used. Alexa Fluor 594 and Alexa Fluor
488-conjugated secondary antibodies (Invitrogen) were
applied appropriately. DAPI was used for nuclear coun-
terstaining. To detect vascular density in the infarct
area, a rat anti-mouse CD31 antibody was used. For
immunohistochemistry, the endogenous peroxides were
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for 10 minutes. After being blocked with 10% goat
serum in PBS, the sections were stained with primary
antibody (mouse monoclonal anti-GFP, Abcam 1:500)
overnight at 4°C, biotinylated secondary antibody for
45 minutes at 37°C, and diaminobenzidine reagent
(Vector Laboratories) for 4 minutes. The numbers of
BM-derived renal stem cells and capillary vessels were
counted by a blinded investigator (LH) in 10 randomly
selected high-power fields (HPF) using a fluorescence
microscope (×400) [12]. The blood vessel density was
expressed as capillaries/HPF (×400). The numbers of
BM-derived renal stem cells were counted as GFP+Sca-
1+ cells/HPF and GFP+c-Kit+ cells/HPF (×400).
Statistical analysis
All data are expressed as mean values ± SEM. One-way
analysis of variance was employed for comparing differ-
ences between groups. Least significant difference (equal
variances) and Dunnett’s T3 (non-equal variances) post
hoc tests were used for testing the differences betweenFigure 1 Engraftment of BM derived cells into I/R-injured kidneys. (A)
from GFP mice. Representative peripheral blood from wild-type (WT) mice
CD45 expression in recipient mice was also evaluated at the same time po
cell was observed in WT mice, while donor derived GFP+ cells were widely
BM-derived cells to the injured kidney compared to the saline-treated micegroups. All tests were two-tailed, and significance was
accepted at P < 0.05.
Results
Hematopoietic reconstruction and engraftment of GFP
positive cells into damaged kidney
Five weeks after BMT, hematopoietic reconstruction of
recipient mice were confirmed by robust expression of
GFP (83.0 ± 4.2%) and CD45 (93.4 ± 5.2%) in peripheral
blood by FACS analysis (Figure 1A). Four weeks after I/R
injury, kidneys were harvested and the engraftment of
BM-derived GFP+ cells into damaged kidneys was evalu-
ated by histology. There were widespread GFP+ cells
infiltrated in the injured kidney of saline-treated group,
implicating the migration and engraftment of BM
derived stem cells into kidneys. What is intriguing, much
more GFP+ cells were observed in the G-CSF adminis-
tered mice compared to the saline-treated ones. But no
GFP+ cells were detected in the damaged kidney of wild
type (WT) mice (Figure 1B). Furthermore, GFP expres-
sion in kidney from chimeric mice that underwent I/RConfirmation of chimerism in mice transplanted with bone marrow
and chimeric BMT mice 5 weeks after BMT were analysised by FACS.
int. (B) BM-derived GFP positive cells within recipient kidneys. No GFP+
infiltrated in saline-treated mice. G-CSF administration mobilized more
. Nuclei were stained with DAPI (blue). Scale bars = 50 μm.
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Additional file 1: Figure S1 showed that GFP+ cells loca-
lized in the glomeruli and interstitium in consecutive
sections of the injured kidney from the mice sacrificed
6 months after ischemic injury.
Bone marrow-derived cells can acquire renal stem cells
properties
BM derived stem cells differentiation and acquisition of
renal fate involved the engraftment of the donor cells
within the host kidney. 4 weeks after injury, transplanted
BM derived stem cells were seeded within renal tubules
and were integrated structurally with resident cells. How-
ever, most BM derived stem cells were CD45-negative
(data not shown). The presence of GFP was used to dis-
tinguish resident from injected CD45-positive cells.
Immunostaining demonstrated that BM-derived cells
contributed to the Sca-1+ or c-Kit+ renal stem cells, al-
though most renal stem cells came from indigenous cells
(Figure 2A). Some Sca-1+ or c-Kit+ cells were detected in
the engrafted BM derived stem cells (Figure 2A), and
more Sca-1+/GFP+ or c-Kit+/GFP+ renal stem cells in the
ischemic kidneys (Figure 2B-C), which suggesting that
the renal microenvironment may change the fate of BM
derived stem cells, and BM derived stem cells home to
the kidney where they lose the hematopoietic phenotype
and acquire renal stem cells lineage.Figure 2 BM derived stem cells can acquire renal stem cells character
showed in merge (arrowhead). Nuclei were stained with DAPI (blue). Scale
analysis of renal stem cells revealed that G-CSF administration nearly doub
*P < 0.05 vs. 4w Saline group; #P < 0.05 vs. 8w Saline group. (C) Quantitativ
(×400).G-CSF can mobilize BM-derived stem cells and enhance
differentiation of BM cells into renal stem cells
To determine whether G-CSF induced stem cells
mobilization would affect renal recovery, FACS and
immunohistology analysis were carried out. Analysis of
peripheral blood revealed that one day after last injec-
tion of G-CSF, all of the stem cell markers were
increased in peripheral blood mobilized with G-CSF as
compared with control group (Figure 3). There was a
kind of respectively more than 2-fold increase in the
total number of CD34+, Sca-1+ or c-Kit+ cells in
cytokine-treated animals compared with controls. How-
ever, G-CSF treatment did not lead to significantly
increased numbers of circulating CD45+ cells compared
with controls (91.1 ± 5.3% versus 96.8 ± 6.5%, P > 0.05).
Furthermore, 4 weeks after I/R injury, the flow cyto-
metry examination of kidney cells revealed the number
of BM-derived GFP+ cells and the apparent populations
of stem cells in the adult kidneys. G-CSF promoted
more stem cell engraftment in damaged kidneys com-
paring with saline treated (Figure 4). Notably, G-CSF
treatment nearly doubled the frequency of Sca-1
expressing BM-derived GFP+ cells (2.1 ± 0.6% versus
0.9 ± 0.5%). Similarly, G-CSF statistically increased the
Sca-1+/GFP+ cells, through immunofluorescence stain-
ing compared with Saline group (4 w 7.5 ± 1.3 cells/
HPF versus 3.5 ± 0.6 cells/HPF, and 8 w 9.4 ± 1.4 cells/istics. (A) Renal stem cells positive for GFP and Sca-1 or c-Kit were
bars = 50 μm (left) and 5 μm (right), respectively. (B) Quantitative
led the frequency of Sca-1 expressing BM-derived renal stem cells.
e analysis of c-Kit positive renal progenitor cells. HPF: high-power field,
Figure 3 G-CSF increased the mobilization of BM stem cells into peripheral blood. (A) FACS analysis of peripheral blood, saline (red line) or
G-CSF (green line). (B) Quantitative analysis of cell markers examined by FACS. Comparing with saline group, G-CSF group expressed higher stem
cell markers such as Sca-1, c-Kit, Flk-1, CD29 and CD34.
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Although G-CSF also promoted GFP+ BM stem cells
differentiation into c-Kit+ renal stem cells, the increased ex-
tent was lower than Sca-1+ GFP+ cells. (Figures 2 B-C, 4).
BM-derived stem cells mediated protective effects for
renal ischemia-injury
To study the profitably angiogenic and/or vasculogenic
effects of BM-derived stem cells at week 4 after ischemia,
the renal sections were examined by immunofluorescence.
CD105, one marker of endothelial cells, was found to be
co-expressed in some subset of GFP+ cells (Figure 5A).
Sections were also stained with smooth muscle marker α-
SMA, a part of GFP co-expressing cells showed good
match with α-SMA-positive cells in post-ischemic kidneys
(Figure 5B). Besides, as shown in Figure 5C, anti-CD31
staining revealed higher microvessels density (MVD) in
the G-CSF treated group comparing to the control group(31.4 ± 4.9 capillaries/HPF versus 20.5 ± 3.1 capillaries/
HPF, P < 0.05, Figure 5C, D). We have also assessed the
histological changes in kidney by H&E staining of sham-
operated, saline-treated, and G-CSF-treated groups in
short and long term following I/R injury (Figure 6). At day
3, there was extensive tubular swelling, necrosis in saline-
treated group. In contrast, kidneys from G-CSF treated
group showed slight tubular swelling after acute injury,
but no renal damage was observed in sham-operated
group. By day 28, necrotic injury almost disappeared and
regenerating cells were observed to cover the tubules in
both saline- and G-CSF-treated groups.
Discussion
Although therapeutic administration in animal models
of acute renal injury suggested that BM stem cells based
therapy may improve the recovery of both glomerular
and tubular compartments, the suitability of these cell
Figure 4 G-CSF increased the differentiation efficiency of BM stem cells into renal stem cells. (A) 4 weeks after I/R injury, FACS analysis BM
derived GFP+ cells in kidney. The Sca-1+/GFP+ cells were significantly up-regulated in G-CSF treated groups (purple box). (B) Evaluation of GFP
positive stem cells in kidney cells by FACS. *P < 0.05 vs. 4w Saline group.
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investigated so far. In this study, our results indicate that
transplanted BM derived stem cells can engraft, survive
in kidney with ischemia injury, and acquire the renal
stem cells phenotypes restoring renal ischemia injury.
Our studies revealed here for the first time that BM
derived stem cells could differentiate into renal stem
cells and integrate with host renal cells. Furthermore,
this process can be enhanced by G-CSF administration.
Recent works have documented the presence of a res-
ervoir of stem and progenitor cells in the interstitium,
papilla, urinary pole of kidney and these cells have been
successfully isolated and expanded ex vivo [3-10]. The
surface markers, such as CD133, CD24, PAX-2, c-Kit
and Sca-1, were exploited to define putative renal stem/
progenitor cells in kidney [5,6]. These cells, lacked
hematopoietic markers, demonstrated self-renewal under
culture conditions, and differentiated into epithelial and
endothelial cell types in vitro and incorporated into
tubules following glycerol induced tubular necrosis
in vivo [6,8]. Several works using renal stem cells also
have demonstrated significant improvement in renal
function after renal progenitor cells injection [4,16,17].
However, they more focus on the identification of stemcells, and reckon without the isolation efficacy of this
kind of cells. The demand for renal stem cells is increas-
ing for end-stage renal disease (ESRD) due to severe
shortage of donor organs. Furthermore, as end stage of
CKD, kidneys of ESRD are already small and fibrotic, en-
dogenous renal stem cells have exhausted and other ori-
gins should be investigated.
The bone marrow constitutes the main reservoir of
stem cells, and these cells can egress from the marrow
niches, enter the systemic circulation [14]. The role of
BM derived stem cells in repair or rejuvenation of tis-
sues and organs that undergo injuries or degeneration
has been drawn increasing attention. It was previously
proposed that bone marrow derived cells could differen-
tiate into renal cells and contribute to kidney regener-
ation following renal ischemia/reperfusion injury [15,18].
However, subsequent studies have demonstrated that
only a few bone marrow derived cells engraft injured
tubules and that their overall contribution to renal repair
was negligible [19-21]. Recent results showed that bone
marrow derived cells could migrate to damaged kidneys
and participate in functional and structural recovery [22-
24]. Furthermore, several studies demonstrated that the
infusion of human or mice derived MSCs contribute to
Figure 5 Analysis of neovascularization. (A) Agiogenesis of BM-derived CD105+ endothelial cells and confirmed by GFP co-expression
(arrowhead). Scale bars = 50 μm (upward) and 20 μm (below), respectively. (B) Immunostaining of α-SMA and GFP demonstrating functional
vessels formation of BM derived cells (arrowhead). Nuclear was stained with DAPI. Scale bars = 50 μm (upward) and 5 μm (below), respectively.
(C & D) Quantitative analysis revealed G-CSF administration can increase capillary density significantly comparing to sham and saline groups.
Nuclear was stained with DAPI. Scale bar = 50 μm.
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Figure 6 G-CSF administration can improve kidney recovery from I/R injury. Representative H&E staining of kidney sections at day 3 and
day 28 after I/R injury. At day 3, tubular swelling, necrosis can be detected in saline-treated group (green arrow), but minor damage in G-CSF
group. No renal damage could be observed in sham-operated group. At day 28, there are no significant differences among saline, sham,
G-CSF groups. Scale bar =50 μm.
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blood-borne renal cells may be detected exclusively
when the peripheral blood contains a large number of
transplanted BM derived stem cells in long term. In this
study, we set up BMT model other than bone marrow
cells injection directly into kidney. The transplanted
GFP+ stem cells will migrate via the bloodstream
throughout all experimental courses for several months,
which would increase the possibility of BM derived stem
cells residing in kidney and the usage of G-CSF would
mobilize more HSCs into circulation. We confirmed that
BM cells can integrate into damaged kidney. Moreover,
we found for the first time that BM cells can differenti-
ate into Sca-1+/CD45-, or c-Kit+/CD45- renal stem cells
over one to two months.
The efficiency of BM cell-based therapy to augment re-
covery from damaged tissues depends on not only effi-
cient delivery of these cells to the desired target tissue,
but also sufficient amount of stem cells. HSCs are unique
in their ability to migrate to various sites, ensuring the
safety and integrity of their regenerative potential. How-
ever, the number of traffic HSCs in blood stream is at an
extremely low level. G-CSF has been used for the collec-
tion of BM cells used in allogeneic or syngeneic stem cell
transplantation [27,28]. After G-CSF mobilization, the
HSCs can release from their storage niche into circula-
tion, ending their journey in the injured organs. We con-
firmed that G-CSF-treatment would mobilize BM stem
cells from the bone marrow into ischemic kidneys and
increase BM-derived renal stem cells after acute kidney
ischemia, which perhaps is one of mechanisms of
damaged kidney repair given by G-CSF. Previous reports
showed that G-CSF stimulates angiogenesis in infracted
kidneys, which acts to promote functional recovery ofthe damaged tissue [2,28,29]. These observations are
based on the fact that HSCs mobilized by G-CSF can dif-
ferentiate into vascular endothelial cells. A secondary
finding in their studies, which was not explored further,
was the beneficial effects of angiogenesis. Through in-
creasing the vessel density, raising blood flow, G-CSF
may enhance more BM-derived stem cells cycling and
storing in the ischemic kidneys, and then the environ-
ment of injured kidneys may induce BM-derived cells in-
corporating into renal cells, getting the phenotypes of
renal progenitors, differentiating into renal stem cells
and terminal cells, finally participating in kidney func-
tional repair. In addition, BM derived stem cells formed
nested capillaries that might be helpful in supplying more
oxygen and providing secondary protection of tubular
cells [5]. Further studies are required to provide insight
into the mechanisms.
Conclusion
In conclusion, the results of the present study confirmed
that bone marrow derived stem cells could differentiate
into renal stem cells. Furthermore, G-CSF enhanced re-
cruitment of BM-derived renal progenitor cells and neo-
vascularization in a murine AKI model to promote
repair. The result of this study opens a new perspective
for bone marrow therapy in kidney injury.
Additional file
Additional file 1: Figure S1. Immunohistochemical staining of GFP. Six
months after I/R injury, consecutive sections of kidney were prepared and
stained with GFP antibody or PBS (as control) and subsequently
diaminobenzidine (DAB). GFP expression is observed in the glomeruli and
interstitium. Arrows in (D) indicate the corresponding glomeruli in (A).
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×200 (C, F).
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